Shares of Second Sight Medical Products Inc (NASDAQ:EYES) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $5.00 for the company and are forecasting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Second Sight Medical Products an industry rank of 160 out of 265 based on the ratings given to its competitors.
EYES has been the topic of a number of analyst reports. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Second Sight Medical Products in a research report on Monday, November 6th.
Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $1.54 million. Second Sight Medical Products had a negative return on equity of 184.87% and a negative net margin of 565.12%. equities research analysts anticipate that Second Sight Medical Products will post -0.55 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Second Sight Medical Products stock. Vanguard Group Inc. raised its holdings in Second Sight Medical Products Inc (NASDAQ:EYES) by 0.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 843,462 shares of the medical device company’s stock after purchasing an additional 5,973 shares during the quarter. Vanguard Group Inc. owned 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent SEC filing. Institutional investors own 12.70% of the company’s stock.
WARNING: “Zacks: Analysts Set $5.00 Price Target for Second Sight Medical Products Inc (EYES)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/22/zacks-analysts-set-5-00-price-target-for-second-sight-medical-products-inc-eyes.html.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.